Donatienne Taylor
Namur, WAL, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN study.
Journal: Breast cancer research and treatment
Published: February 28, 2026
Long-term immune response to mRNA anti-SARS-CoV-2 vaccination in patients with cancer.
Journal: Frontiers in immunology
Published: February 23, 2026
Personalized ctDNA detection and genomic profiling in the NeoRHEA Study.
Journal: NPJ breast cancer
Published: June 21, 2025
Palbociclib plus letrozole versus weekly paclitaxel, both in combination with trastuzumab plus pertuzumab, as neoadjuvant treatment for patients with HR-positive/HER2-positive early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17).
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: June 05, 2025
Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International Study.
Journal: Clinical breast cancer
Published: February 27, 2025
The Challenge of Calculating EUSOMA Quality Indicators with Administrative Data: A Pilot Study in Belgium.
Journal: Breast care (Basel, Switzerland)
Published: October 22, 2024
Higher relative survival in breast cancer patients treated in certified and high-volume breast cancer centres - A population-based study in Belgium.
Journal: European journal of cancer (Oxford, England : 1990)
Published: April 18, 2024
Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.
Journal: Nature communications
Published: December 12, 2023
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.
Journal: Nature communications
Published: July 27, 2023
Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab.
Journal: Critical reviews in oncology/hematology
Published: March 03, 2023
Machine Learning Algorithm to Estimate Distant Breast Cancer Recurrence at the Population Level with Administrative Data.
Journal: Clinical epidemiology
Published: December 03, 2022
ROSALINE: a phase II, neoadjuvant study targeting ROS1 in combination with endocrine therapy in invasive lobular carcinoma of the breast.
Journal: Future oncology (London, England)
Published: June 13, 2022
Last Updated: 09/26/2026